ASX Penny Stocks To Watch In October 2026

As the Australian market prepares for a potentially positive start to the week, investor attention is drawn to global influences such as Wall Street's mixed signals and rising bond yields. Amidst these broader market dynamics, penny stocks continue to capture interest due to their unique blend of affordability and growth potential. While often associated with smaller or newer companies, these stocks can offer compelling opportunities when backed by strong financials, making them an intriguing option for those looking beyond traditional investment avenues.

Here we highlight a subset of our preferred stocks from the screener.

Arovella Therapeutics (ASX:ALA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Arovella Therapeutics Limited is a biotechnology company focused on developing cancer therapies in Australia and internationally, with a market cap of A$66.49 million.

Operations: The company's revenue is derived from its Pharmaceutical Development segment, totaling A$3.50 million.

Market Cap: A$66.49M

Arovella Therapeutics, with a market cap of A$66.49 million, is pre-revenue and focused on developing cancer therapies. Despite being unprofitable with a net loss of A$6.92 million for the year ended June 2026, it maintains a cash runway exceeding two years and is debt-free. The management team and board are relatively new, indicating potential strategic shifts as highlighted in recent shareholder communications about advancing its iNKT cell therapy platform. Recent amendments to company bylaws aim to incentivize non-executive directors through equity-based compensation, reflecting efforts to align leadership interests with shareholder value creation.

• Click here and access our complete financial health analysis report to understand the dynamics of Arovella Therapeutics.
• Understand Arovella Therapeutics' track record by examining our performance history report.

Macmahon Holdings (ASX:MAH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Macmahon Holdings Limited provides surface and underground mining, as well as mining support and civil infrastructure services to companies in Australia and Southeast Asia, with a market capitalization of A$2.49 billion.

Operations: The company's revenue is primarily derived from its Mining segment, which generated A$1.93 billion, followed by the Civil segment with A$672.43 million.

Market Cap: A$2.49B

Macmahon Holdings, with a market cap of A$2.49 billion, demonstrates solid financial health with its operating cash flow covering 92.3% of its debt and short-term assets exceeding liabilities. The company reported revenue growth to A$2.62 billion and net income rising to A$101.14 million for the year ended June 2026, indicating strong operational performance despite a low return on equity of 13.7%. Recent board changes reflect strategic alignment with major shareholder PT Amman Mineral Internasional Tbk's interests, while dividend increases signal confidence in future earnings as guidance suggests potential revenue growth to up to A$3.05 billion for fiscal 2027.

• Click to explore a detailed breakdown of our findings in Macmahon Holdings' financial health report.
• Gain insights into Macmahon Holdings' future direction by reviewing our growth report.

S2 Resources (ASX:S2R)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: S2 Resources Ltd is involved in mineral exploration activities mainly in Australia and Finland, with a market cap of A$42.53 million.

Operations: The company generates revenue from its exploration activities in Australia, amounting to A$0.51 million.

Market Cap: A$42.53M

S2 Resources, with a market cap of A$42.53 million, has transitioned to profitability in the past year, reporting a net income of A$12.73 million for the full year ended June 30, 2026. Despite being pre-revenue with only A$0.51 million generated from exploration activities, S2 Resources showcases strong financial health by maintaining no debt and having short-term assets significantly exceeding liabilities. Its Price-To-Earnings ratio of 3.3x suggests it may be undervalued compared to the broader Australian market average of 16.1x, while its Return on Equity stands at an outstanding 50.2%.

• Jump into the full analysis health report here for a deeper understanding of S2 Resources.
• Gain insights into S2 Resources' historical outcomes by reviewing our past performance report.

Make It Happen

• Jump into our full catalog of 408 ASX Penny Stocks here.
• Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com